title: Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy.
abstract: OBJECTIVE
  Identify prognostic factors that influence outcome after unrelated donor bone marrow transplantation in children with acute myeloid leukemia (AML).
  
  
  METHODS
  Included are 268 patients (age <or= 18 years) with AML in second complete remission (n = 142), relapse (n = 90), or primary induction failure (n = 36) at transplantation. All patients received bone marrow grafts from an unrelated donor and a myeloablative conditioning regimen. Cox regression models were constructed to identify risk factors that influence outcome after transplantation.
  
  
  RESULTS
  In this analysis, the only risk factor that predicted leukemia recurrence and overall and leukemia-free survival was disease status at transplantation. The 5-year probabilities of leukemia-free survival were 45%, 20%, and 12% for patients who underwent transplantation at second complete remission, relapse, and primary induction failure, respectively. As expected, risk of acute but not chronic graft-versus-host disease (GVHD) was lower with T-cell-depleted bone marrow grafts; T-cell-depleted grafts were not associated with higher risks of leukemia recurrence. We observed similar risks of leukemia relapse in patients with and without acute and chronic GVHD.
  
  
  CONCLUSIONS
  Children who underwent transplantation in remission had a superior outcome compared with children who underwent transplantation during relapse or persistent disease. Nevertheless, 20% of children who underwent transplantation in relapse are long-term survivors, suggesting that unrelated donor bone marrow transplantation is an effective therapy in a significant proportion of children with recurrent or primary refractory AML.
authors.affiliation: Children's Hospital of Philadelphia, Philadelphia, USA.
authors.forename: Nancy J
authors.initials: NJ
authors.lastname: Bunin
authors.forename: Stella M
authors.initials: SM
authors.lastname: Davies
authors.forename: Richard
authors.initials: R
authors.lastname: Aplenc
authors.forename: Bruce M
authors.initials: BM
authors.lastname: Camitta
authors.forename: Kenneth B
authors.initials: KB
authors.lastname: DeSantes
authors.forename: Rakesh K
authors.initials: RK
authors.lastname: Goyal
authors.forename: Neena
authors.initials: N
authors.lastname: Kapoor
authors.forename: Nancy A
authors.initials: NA
authors.lastname: Kernan
authors.forename: Joseph
authors.initials: J
authors.lastname: Rosenthal
authors.forename: Franklin O
authors.initials: FO
authors.lastname: Smith
authors.forename: Mary
authors.initials: M
authors.lastname: Eapen
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000401:mortality / Q000628:therapy*; D008297:Male; D011379:Prognosis; D016016:Proportional Hazards Models; D012074:Remission Induction; D012307:Risk Factors; D014019:Tissue Donors
chemical_list: D000970:Antineoplastic Agents
references.citation: Leukemia. 2005 Dec;19(12):2125-9
references.pmid: 16281077
references.citation: Leukemia. 2005 Dec;19(12):2130-8
references.pmid: 16304572
references.citation: Stat Med. 1999 Jun 30;18(12):1489-500
references.pmid: 10398287
references.citation: Leukemia. 2005 Dec;19(12):2054-62
references.pmid: 16136168
references.citation: Hematol Oncol Clin North Am. 1999 Oct;13(5):1091-112, viii-ix
references.pmid: 10553263
references.citation: Leukemia. 2005 Dec;19(12):2101-16
references.pmid: 16136167
references.citation: Leukemia. 1999 Jan;13(1):25-31
references.pmid: 10049056
references.citation: Cancer. 2007 Jan 1;109(1):157-63
references.pmid: 17133407
references.citation: Lancet. 2007 Jun 9;369(9577):1947-54
references.pmid: 17560447
references.citation: Lancet. 2005 Aug 27-Sep 2;366(9487):733-41
references.pmid: 16125590
references.citation: Blood. 2007 Dec 15;110(13):4576-83
references.pmid: 17785583
references.citation: J Clin Oncol. 2005 Dec 20;23(36):9172-8
references.pmid: 16361619
references.citation: Biol Blood Marrow Transplant. 2006 Aug;12(8):876-84
references.pmid: 16864058
references.citation: Blood. 2003 Feb 15;101(4):1611-9
references.pmid: 12393725
references.citation: J Clin Oncol. 2003 Aug 1;21(15):2940-7
references.pmid: 12885813
references.citation: Bone Marrow Transplant. 1995 Jun;15(6):825-8
references.pmid: 7581076
references.citation: Blood. 2001 Jan 1;97(1):56-62
references.pmid: 11133742
references.citation: Leukemia. 1998 Oct;12(10):1534-8
references.pmid: 9766496
references.citation: J Clin Oncol. 2003 Dec 1;21(23):4377-85
references.pmid: 14645428
references.citation: Leukemia. 2005 Dec;19(12):2030-42
references.pmid: 16304570